The discovery that NOTCH1 pathway activation is associated with aggressive ACC led to clinical trials of NOTCH inhibitors in NOTCH‐activated ACC [12, 13, 14]. This evidence concerns the gene NOTCH1 and adrenal cortex carcinoma.